A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Summary

This is a multicenter expanded access study of zanubrutinib monotherapy for participants with B-cell malignancies who are ineligible to enroll into any available zanubrutinib clinical trials

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications